The Crohn's Disease market size growth is expected to be mainly driven by the entry of novel therapies with better clinical profiles and patient convenient RoA.
LAS VEGAS, July 29, 2021 /PRNewswire/ -- DelveInsight's Crohn's Disease (CD) Marketreport offers comprehensive coverage of the current treatment practices, pipeline drugs, Crohn's Disease market share of the individual therapies, current and forecasted Crohn's Disease market size from 2018 to 2030 segmented into 7MM (the USA, EU5 (the UK, Italy, Spain, France, and Germany), and Japan).
The United States accounted for the maximum Crohn's Disease prevalent cases in the 7MM with 825,165 cases in the year 2020. Furthermore, the prevalence is expected to grow more during the forecast period, 2021–2030.
The US FDA-approved biologics in the Crohn's Disease treatment market include infliximab, adalimumab, certolizumab, vedolizumab, natalizumab, ustekinumab.
Out of all the available biologics, anti-TNF agents mainly adalimumab and infliximab dominate the market, however, classes such as anti-integrin and interleukin inhibitor are making inroads into the CD market owing to better clinical profile (i.e. no black box warnings) and also patient convenient dosing.
Adalimumab is expected to hold the maximum market share by 2023 after which biosimilars in the case of the US are expected to enter and will erode the sales value.
Key pharma giants including Eli Lilly, RedHill Biopharma, AbbVie, Gilead Sciences, and Galapagos NV, Celgene, Janssen Pharmaceuticals, among several others are actively involved in advancing the Crohn's Disease Pipeline.
Emerging Crohn's Disease pipeline therapies including Jyselica, Rinvoq, Etrolizumab, Ozanimod, Skyrizi, Brazikumab, Alofisel, Mirikizumab, RHB-104, Etrasimod, Tremfya, Deucravacitinib, Tesnatilimab, Sibofimloc, BT-11, UTTR1147A, TD-1473, JNJ-67864238, SHR0302, Ryoncil, Ritlecitinib, are undergoing different stages of clinical development.
Out of all emerging therapies, Ozanimod is expected to nab the highest patient share owing to once-daily oral dosing, the potential for a differentiated cardiovascular profile compared to JAKs class, and promising efficacy signals from the phase 2 STEPSTONE study.
Risankizumab (AbbVie) is anticipated to emerge as a potential therapy in the Crohn's Disease market based on its results from two Phase III induction studies.
An anticipated increase in the market penetration of targeted/ advanced therapies in tandem with advances in R&D, development of new biomarkers for diagnosis, and increasing prevalence of CD shall further supply the fuel for Crohn's Disease Market share growth.
Crohn's Disease (CD) is one of the major types of Inflammatory Bowel Disease (IBD), other being ulcerative colitis (UC). CD is typically more severe than UC but is slightly less common. The disease can occur at any age, but CD is most often diagnosed in adolescents and adults between the ages of 20 and 30.
It causes inflammation of the digestive tract, leading to abdominal pain, severe diarrhea, fatigue, weight loss, and malnutrition. Crohn's Disease primarily affects the small intestine and the beginning of the large intestine, however, the disease can affect any part of a patients' digestive tract, from mouth to anus.
The present Crohn's Disease treatment market size includes drug therapies and surgeries. The treatment approaches vary with severity levels, with an ultimate goal to maintain clinical remission. The pharmacologic Crohn's Disease treatment strategy includes the prescription of aminosalicylates (sulfasalazine), antibiotics or corticosteroids (budesonide). Once remission is achieved, patients are normally maintained with escalation to the highly effective but potentially more toxic treatments, such as prednisone, immunomodulators (azathioprine, mercaptopurine, and methotrexate). For those who do not get into remission with conventional therapy, escalation to the highly effective but potentially more toxic treatment strategies treatment with biologics (infliximab, adalimumab, certolizumab, vedolizumab, natalizumab, ustekinumab) is typically indicated.
Targeted therapies (mainly biologics) appear to be deeply penetrated into the Crohn's Disease treatment market in case of moderate to severe CD patients occupying around 40%-50% of the current Crohn's Disease treatment market. The reason can be due to the availability of relatively more products with better clinical profile and patient convenient RoA. The Biologics Crohn's Disease market is dominated by anti-TNF agents mainly adalimumab and infliximab. However, after the patent expiries of the available biologics (such as for Adalimumab 2023) after which biosimilars in the case of the US are expected to enter and erode the sales value.
At present, some companies have indulged themselves in initiating clinical trials that investigate new treatment options or studying how to use existing treatment options better. Current ongoing trials evaluate therapies with novel MOAs that are less immunogenic than current offerings and many new classes of therapies are looking to enter the market over the next 10 years.
Key players such as Gilead Sciences and Galapagos, AbbVie and Boehringer Ingelheim, Takeda Pharmaceuticals, Eli Lilly and Company, RedHill Biopharma, Roche, AbbVie, Celgene, AstraZeneca, Mesoblast, Arena Pharmaceuticals, Janssen, and several others are investigating their candidates for the management of Crohn's Disease in the United States.
A lack of effective and timely diagnosis of the disease leads to a complicated disease course with an increased number of surgeries. The CD market offers expensive biologics as a standard treatment option, however, the associated cost makes their adoption and accessibility highly limited.
Nevertheless, the treatment market comprises majorly targeted therapies (mainly biologics) expected to penetrate the market in next decade owing to the easy availability and better clinical profile. This offers a gamut of opportunities to the several pharmaceutical and biotech companies to investigate and launch novel drugs with different target areas, novel MOAs and less immunogenicity than the currently available Crohn's Disease therapies. Better awareness around the condition is also expected to fuel the growth of Crohn's Disease therapy market owing to timely treatment intervention.
The patent expiries of market-leading therapies such as Remicade, Humira, Entyvio and Stelara are anticipated to dilute the Crohn's Disease market value, leading to the entry of biosimilars that shall give tough competition to upcoming expensive biologics in the pipeline.
Key Pharmaceutical companies include Pfizer (Comirnaty), AstraZeneca (Vaxzevria/Covishield), Moderna (mRNA-1273), Janssen (Ad26.COV2.S), Gamaleya Research Institute (Sputnik V), Sinovac (CoronaVac), CanSino Biologics (Convidicea (Ad5-nCoV)), among others.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platformPharmDelve.